{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:16:06Z","timestamp":1788830166304,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["FWOAL806"],"award-info":[{"award-number":["FWOAL806"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["SRP48"],"award-info":[{"award-number":["SRP48"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple myeloma (MM) remains an incurable cancer despite advances in therapy. Therefore, the search for new targets is still essential to uncover potential treatment strategies. Metabolic changes, induced by the hypoxic bone marrow, contribute to both MM cell survival and drug resistance. Pyrroline-5-carboxylate reductase 1 and 2 (PYCR1 and PYCR2) are two mitochondrial enzymes that facilitate the last step in the glutamine-to-proline conversion. Overexpression of PYCR1 is involved in progression of several cancers, however, its\u2019 role in hematological cancers is unknown. In this study, we investigated whether PYCR affects MM viability, proliferation and response to bortezomib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Correlation of PYCR1\/2 with overall survival was investigated in the MMRF CoMMpass trial (653 patients). OPM-2 and RPMI-8226 MM cell lines were used to perform in vitro experiments. RPMI-8226 cells were supplemented with <jats:sup>13<\/jats:sup>C-glutamine for 48\u00a0h in both normoxia and hypoxia (&lt;\u20091% O<jats:sub>2<\/jats:sub>, by chamber) to perform a tracer study. PYCR1 was inhibited by siRNA or the small molecule inhibitor pargyline. Apoptosis was measured using Annexin\u00a0V and 7-AAD staining, viability by CellTiterGlo assay and proliferation by BrdU incorporation. Differential protein expression was evaluated using Western Blot. The SUnSET method was used to measure protein synthesis. All in vitro experiments were performed in hypoxic conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that PYCR1 and PYCR2 mRNA expression correlated with an inferior overall survival. MM cells from relapsed\/refractory patients express significantly higher levels of PYCR1 mRNA. In line with the strong expression of PYCR1, we performed a tracer study in RPMI-8226 cells, which revealed an increased conversion of <jats:sup>13<\/jats:sup>C-glutamine to proline in hypoxia. PYCR1 inhibition reduced MM viability and proliferation and increased apoptosis. Mechanistically, we found that PYCR1 silencing reduced protein levels of p-PRAS40, p-mTOR, p-p70, p-S6, p-4EBP1 and p-eIF4E levels, suggesting a decrease in protein synthesis, which we also confirmed in vitro. Pargyline and siPYCR1 increased bortezomib-mediated apoptosis. Finally, combination therapy of pargyline with bortezomib reduced viability in CD138<jats:sup>+<\/jats:sup>\u2009MM cells and reduced tumor burden in the murine 5TGM1 model compared to single agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p> This study identifies PYCR1 as a novel target in bortezomib-based combination therapies for MM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02250-3","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T06:03:08Z","timestamp":1643695388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis"],"prefix":"10.1186","volume":"41","author":[{"given":"Inge","family":"Oudaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Satilmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Vlummens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"De Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Ghesqui\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-6581","authenticated-orcid":false,"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"2250_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2250_CR2","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"J Abdi","year":"2013","unstructured":"Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186\u2013207.","journal-title":"Oncotarget"},{"key":"2250_CR3","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","volume":"7","author":"L Di Marzo","year":"2016","unstructured":"Di Marzo L, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016;7:60698\u2013711.","journal-title":"Oncotarget"},{"key":"2250_CR4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"key":"2250_CR5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","volume":"17","author":"Y Nefedova","year":"2003","unstructured":"Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17:1175\u201382.","journal-title":"Leukemia"},{"key":"2250_CR6","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52\u201361.","journal-title":"Ann Oncol"},{"key":"2250_CR7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284\u201390.","journal-title":"Haematologica"},{"key":"2250_CR8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2147\/DDDT.S198117","volume":"13","author":"Z Ye","year":"2019","unstructured":"Ye Z, Chen J, Xuan Z, Yang W. Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:1707\u201316.","journal-title":"Drug Des Devel Ther"},{"key":"2250_CR9","doi-asserted-by":"crossref","first-page":"10189","DOI":"10.1074\/jbc.M210837200","volume":"278","author":"KS Kovacina","year":"2003","unstructured":"Kovacina KS, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189\u201394.","journal-title":"J Biol Chem"},{"key":"2250_CR10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/1061186X.2021.1882470","volume":"29","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Tang S, Zhang X, Chen L. Targeting PRAS40: a novel therapeutic strategy for human diseases. J Drug Target. 2021;29:703\u201315.","journal-title":"J Drug Target"},{"key":"2250_CR11","doi-asserted-by":"crossref","first-page":"E1205","DOI":"10.1152\/ajpendo.00177.2003","volume":"285","author":"CH Lang","year":"2003","unstructured":"Lang CH, et al. Alcohol impairs leucine-mediated phosphorylation of 4E-BP1, S6K1, eIF4G, and mTOR in skeletal muscle. Am J Physiol Endocrinol Metab. 2003;285:E1205-1215.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2250_CR12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/jcr.1925.148","volume":"9","author":"O Warburg","year":"1925","unstructured":"Warburg O. The metabolism of carcinoma cells. Journal of Cancer Research. 1925;9(1):148\u201363.","journal-title":"Journal of Cancer Research."},{"key":"2250_CR13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927;8:519\u201330.","journal-title":"J Gen Physiol"},{"key":"2250_CR14","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1111\/cas.14614","volume":"111","author":"S Ikeda","year":"2020","unstructured":"Ikeda S, et al. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma. Cancer Sci. 2020;111:4088\u2013101.","journal-title":"Cancer Sci"},{"key":"2250_CR15","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","volume":"75","author":"P Maiso","year":"2015","unstructured":"Maiso P, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75:2071\u201382.","journal-title":"Cancer Res"},{"key":"2250_CR16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/bloodadvances.2017008847","volume":"2","author":"S Ikeda","year":"2018","unstructured":"Ikeda S, Kitadate A, Abe F, Takahashi N, Tagawa H. Hypoxia-inducible KDM3A addiction in multiple myeloma. Blood Adv. 2018;2:323\u201334.","journal-title":"Blood Adv"},{"key":"2250_CR17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbrc.2017.01.015","volume":"483","author":"ZF Jiang","year":"2017","unstructured":"Jiang ZF, Wang M, Xu JL, Ning YJ. Hypoxia promotes mitochondrial glutamine metabolism through HIF1\u03b1-GDH pathway in human lung cancer cells. Biochem Biophys Res Commun. 2017;483:32\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"2250_CR18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jpedsurg.2006.12.010","volume":"42","author":"H Soh","year":"2007","unstructured":"Soh H, Wasa M, Fukuzawa M. Hypoxia upregulates amino acid transport in a human neuroblastoma cell line. J Pediatr Surg. 2007;42:608\u201312.","journal-title":"J Pediatr Surg"},{"key":"2250_CR19","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.1219555110","volume":"110","author":"F Guillaumond","year":"2013","unstructured":"Guillaumond F, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:3919\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2250_CR20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","volume":"128","author":"M Bolzoni","year":"2016","unstructured":"Bolzoni M, et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood. 2016;128:667\u201379.","journal-title":"Blood"},{"key":"2250_CR21","first-page":"359","volume":"15","author":"W Liu","year":"2013","unstructured":"Liu W, Phang JM. Oncogene and Cancer - From Bench to Clinic. INTECH. 2013;15:359\u201390.","journal-title":"INTECH"},{"key":"2250_CR22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fonc.2020.00776","volume":"10","author":"C D'Aniello","year":"2020","unstructured":"D\u2019Aniello C, Patriarca EJ, Phang JM, Minchiotti G. Proline Metabolism in Tumor Growth and Metastatic Progression. Front Oncol. 2020;10:776.","journal-title":"Front Oncol"},{"key":"2250_CR23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00726-008-0107-9","volume":"35","author":"CA Hu","year":"2008","unstructured":"Hu CA, et al. Functional genomics and SNP analysis of human genes encoding proline metabolic enzymes. Amino Acids. 2008;35:655\u201364.","journal-title":"Amino Acids"},{"key":"2250_CR24","doi-asserted-by":"crossref","first-page":"e45190","DOI":"10.1371\/journal.pone.0045190","volume":"7","author":"J De Ingeniis","year":"2012","unstructured":"De Ingeniis J, et al. Functional specialization in proline biosynthesis of melanoma. PLoS One. 2012;7:e45190.","journal-title":"PLoS One"},{"key":"2250_CR25","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1101\/gr.180101","volume":"11","author":"H Suzuki","year":"2001","unstructured":"Suzuki H, et al. Protein-protein interaction panel using mouse full-length cDNAs. Genome Res. 2001;11:1758\u201365.","journal-title":"Genome Res"},{"key":"2250_CR26","first-page":"731","volume":"15","author":"F Cai","year":"2018","unstructured":"Cai F, et al. Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Oncol Lett. 2018;15:731\u201340.","journal-title":"Oncol Lett"},{"key":"2250_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/carcin\/bgx022","volume":"38","author":"J Ding","year":"2017","unstructured":"Ding J, et al. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis. 2017;38:519\u201331.","journal-title":"Carcinogenesis"},{"key":"2250_CR28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12967-019-2091-0","volume":"17","author":"J Zhuang","year":"2019","unstructured":"Zhuang J, et al. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase\/insulin receptor substrate 1 (JNK\/IRS1) pathway in hepatocellular cancer. J Transl Med. 2019;17:343.","journal-title":"J Transl Med"},{"key":"2250_CR29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ijrobp.2006.07.1381","volume":"66","author":"M De Ridder","year":"2006","unstructured":"De Ridder M, et al. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys. 2006;66:1473\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2250_CR30","first-page":"3980","volume":"120","author":"M Needle","year":"2012","unstructured":"Needle M, et al. The Multiple Myeloma Research Foundation (MMRF) CoMMpass SM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles. Immunophenotypes and Clinical Outcomes. Blood. 2012;120(21):3980.","journal-title":"Immunophenotypes and Clinical Outcomes. Blood."},{"key":"2250_CR31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13148-018-0554-4","volume":"10","author":"L Herviou","year":"2018","unstructured":"Herviou L, et al. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenetics. 2018;10:121.","journal-title":"Clin Epigenetics"},{"key":"2250_CR32","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.bmcl.2019.07.047","volume":"29","author":"K Milne","year":"2019","unstructured":"Milne K, et al. A fragment-like approach to PYCR1 inhibition. Bioorg Med Chem Lett. 2019;29:2626\u201331.","journal-title":"Bioorg Med Chem Lett"},{"key":"2250_CR33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nmeth.1314","volume":"6","author":"EK Schmidt","year":"2009","unstructured":"Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275\u20137.","journal-title":"Nat Methods"},{"key":"2250_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"2250_CR35","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907\u201316.","journal-title":"Blood"},{"key":"2250_CR36","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3389\/fimmu.2018.03083","volume":"9","author":"H Hu","year":"2018","unstructured":"Hu H, Tian M, Ding C, Yu S. The C\/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection. Front Immunol. 2018;9:3083.","journal-title":"Front Immunol"},{"key":"2250_CR37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1074\/mcp.RA119.001390","volume":"18","author":"L Janker","year":"2019","unstructured":"Janker L, et al. Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia. Mol Cell Proteomics. 2019;18:936\u201353.","journal-title":"Mol Cell Proteomics"},{"key":"2250_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2105-12-46","volume":"12","author":"F Liu","year":"2011","unstructured":"Liu F, White JA, Antonescu C, Gusenleitner D, Quackenbush J. GCOD - GeneChip Oncology Database. BMC Bioinformatics. 2011;12:46.","journal-title":"BMC Bioinformatics"},{"key":"2250_CR39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10863-021-09887-3","volume":"53","author":"S Du","year":"2021","unstructured":"Du S, Sui Y, Ren W, Zhou J, Du C. PYCR1 promotes bladder cancer by affecting the Akt\/Wnt\/\u03b2-catenin signaling. J Bioenerg Biomembr. 2021;53:247\u201358.","journal-title":"J Bioenerg Biomembr"},{"key":"2250_CR40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.21037\/atm-19-4402","volume":"8","author":"S Xiao","year":"2020","unstructured":"Xiao S, Li S, Yuan Z, Zhou L. Pyrroline-5-carboxylate reductase 1 (PYCR1) upregulation contributes to gastric cancer progression and indicates poor survival outcome. Ann Transl Med. 2020;8:937.","journal-title":"Ann Transl Med"},{"key":"2250_CR41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.biopha.2018.12.089","volume":"111","author":"D Wang","year":"2019","unstructured":"Wang D, et al. PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488. Biomed Pharmacother. 2019;111:588\u201395.","journal-title":"Biomed Pharmacother"},{"key":"2250_CR42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12032-016-0870-5","volume":"34","author":"T Zeng","year":"2017","unstructured":"Zeng T, et al. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med Oncol. 2017;34:27.","journal-title":"Med Oncol"},{"key":"2250_CR43","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.1038\/srep17206","volume":"5","author":"W Liu","year":"2015","unstructured":"Liu W, Hancock CN, Fischer JW, Harman M, Phang JM. Proline biosynthesis augments tumor cell growth and aerobic glycolysis: involvement of pyridine nucleotides. Sci Rep. 2015;5:17206.","journal-title":"Sci Rep"},{"key":"2250_CR44","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1515\/med-2019-0066","volume":"14","author":"QL Wang","year":"2019","unstructured":"Wang QL, Liu L. PYCR1 is Associated with Papillary Renal Cell Carcinoma Progression. Open Med (Wars). 2019;14:586\u201392.","journal-title":"Open Med (Wars)"},{"key":"2250_CR45","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.2147\/CMAR.S166711","volume":"10","author":"Y Ye","year":"2018","unstructured":"Ye Y, Wu Y, Wang J. Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma. Cancer Manag Res. 2018;10:6399\u2013407.","journal-title":"Cancer Manag Res"},{"key":"2250_CR46","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991\u20136000.","journal-title":"Oncogene"},{"key":"2250_CR47","doi-asserted-by":"crossref","first-page":"e50005","DOI":"10.1371\/journal.pone.0050005","volume":"7","author":"V Ramakrishnan","year":"2012","unstructured":"Ramakrishnan V, et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K\/Akt and MEK\/ERK pathway. PLoS One. 2012;7:e50005.","journal-title":"PLoS One"},{"key":"2250_CR48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3892\/ijo.2014.2774","volume":"46","author":"V Zismanov","year":"2015","unstructured":"Zismanov V, et al. Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E. Int J Oncol. 2015;46:860\u201370.","journal-title":"Int J Oncol"},{"key":"2250_CR49","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020003217","volume":"5","author":"E De Smedt","year":"2021","unstructured":"De Smedt E, et al. G9a\/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. Blood Adv. 2021;5:2325\u201338.","journal-title":"Blood Adv"},{"key":"2250_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-021-02999-5","author":"AN Bogner","year":"2021","unstructured":"Bogner AN, Stiers KM, Tanner JJ. Structure, biochemistry, and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase (PYCR), an emerging cancer therapy target. Amino Acids. 2021. https:\/\/doi.org\/10.1007\/s00726-021-02999-5.","journal-title":"Amino Acids"},{"key":"2250_CR51","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cmet.2016.08.008","volume":"24","author":"N Sahu","year":"2016","unstructured":"Sahu N, et al. Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis. Cell Metab. 2016;24:753\u201361.","journal-title":"Cell Metab"},{"key":"2250_CR52","doi-asserted-by":"crossref","first-page":"76995","DOI":"10.18632\/oncotarget.12765","volume":"7","author":"WJ Leu","year":"2016","unstructured":"Leu WJ, et al. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K\/AKT\/mTOR and c-Myc signaling pathways. Oncotarget. 2016;7:76995\u20137009.","journal-title":"Oncotarget"},{"key":"2250_CR53","volume-title":"Targeting MYC Dependence by Metabolic Inhibitors in Cancer","author":"HS Sabnis","year":"2017","unstructured":"Sabnis HS, Somasagara RR, Bunting KD. Targeting MYC Dependence by Metabolic Inhibitors in Cancer. 8th ed. Basel: Genes; 2017.","edition":"8"},{"key":"2250_CR54","first-page":"743","volume":"97","author":"J Ding","year":"2017","unstructured":"Ding J, et al. The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of colon cancer cells. Zhonghua Yi Xue Za Zhi. 2017;97:743\u20138.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2250_CR55","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.3390\/ijms21176089","volume":"21","author":"KH Lee","year":"2020","unstructured":"Lee KH, et al. Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity. Int J Mol Sci. 2020;21:6089.","journal-title":"Int J Mol Sci."},{"key":"2250_CR56","doi-asserted-by":"crossref","first-page":"18316","DOI":"10.1074\/jbc.RA120.016106","volume":"295","author":"EM Christensen","year":"2020","unstructured":"Christensen EM, et al. screening for proline analog inhibitors of the proline cycle enzyme PYCR1. J Biol Chem. 2020;295:18316\u201327.","journal-title":"J Biol Chem"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02250-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T06:05:21Z","timestamp":1643695521000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02250-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02250-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The housing and treatment of the mice were approved by the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussel (licence No LA1230281, CEP No 20\u2013281-6).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved this manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}